##

- Deep Dive into the Management of Myelodysplastic Syndromes
- The Changing Landscape of Myelodysplastic Syndromes Treatment
- Some Highlighted Studies

##

- Clinical Insights into Managing Myeloma
- Challenges in Multiple Myeloma: Renal Failure
- Some Highlighted Studies

##

- Deciding the Optimum Treatment Options for Acute Myeloid Leukemia
- Deep Dive into the Acute Myeloid Leukemia Treatment Scenario
- New Evidence and Innovative Therapeutics in Acute Myeloid Leukemia
- Some Highlighted Studies

##

##

#### View

# Acute Myeloid Leukemia

### New Evidence and Innovative Therapeutics in Acute Myeloid Leukemia

###### Speaker details: Dr. Harry P. Erba, Dr. Naval Daver, Dr. Gail J. Roboz, Dr. Tara Lin

The Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT) observed that venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in older patients with AML who were fit.31

The randomized, doubleblind, placebo-controlled phase III QUAZAR AML001 trial showed that oral azacitidine maintenance improves survival in transplant-ineligible AML.32

Around 64% of the patients with intensive chemo-ineligible AML treated with magrolimab plus azacitidine achieved an objective response and 56% of patients achieved a complete response (unpublished data).

The VIALE-A trial observed that in previously untreated patients ineligible for intensive chemotherapy, OS was longer, and remission was higher in those who received azacitidine and venetoclax compared to azacitidine alone.33